Performance analysis of global local mean square error criterion of stochastic linearization for nonlinear oscillator

The paper presents a performance analysis of global-local mean square error criterion of stochastic linearization for some nonlinear oscillators. This criterion of stochastic linearization for nonlinear oscillators bases on dual conception to the local mean square error criterion (LOMSEC). The algorithm is generally built to multi-degree of freedom (MDOF) nonlinear oscillators. Then, the performance analysis is carried out for two applications which comprise a rolling ship oscillation and two-degree of freedom one. The improvement on accuracy of the proposed criterion has been shown in comparison with the conventional Gaussian equivalent linearization (GEL)

Comparing Labor Productivity of Vietnam to Some Asian Countries

In Vietnam, social labor productivity is an indicator of the National Statistical Indicator System (specified in the Law on Statistics), which is calculated by the average GDP per employed worker per year. Research results show that in the 2016-2020 period, labor productivity of the whole economy has improved markedly, with an average increase of 5.78%/year in the 2016-2020 period. However, Vietnam’s labor productivity still has internal limitations that have not been overcome. In comparison with selected Asian countries, Vietnam’s labor productivity has a low absolute value despite its relatively high growth since 1991. In most of the sectors compared, it is basically at the lowest level. As a result, proposing solutions to improve and enhance labor productivity aimed at promoting sustainable economic growth in Vietnam in the coming time is an urgent issue for the development of the country

The roles of, activities of, and competencies for, community nursing services in rural Vietnam: Implications for policy decisions

Community health workforce plays a vital role in providing primary health care services as per the needs of residents; however, few studies have examined how nurses work within commune health centers (CHCs). Using qualitative methods including interviews and focus group discussions with key stakeholders, this study explores the roles, activities, and competencies required of community nursing services in rural districts within Vietnam. Two primary roles were identified: CHC nursing and family nursing. For the latter, in addition to providing people with general health care and health communication, they were expected to also deliver psychological care. CHC nursing fulfilled more roles and required four specific competencies: clinical care, communication, management, and planning/coordination activities. Despite these various roles serving people within a community, few ongoing efforts at either the local or national level are aimed at supporting these nurses. The study highlights the need for policy decisions via either developing a new job position policy or adapting the existing policy by integrating new roles into the existing positions of CHC nurses in Vietnam. © 2018 John Wiley & Sons, Ltd. **Please note that there are multiple authors for this article therefore only the name of the first 5 including Federation University Australia affiliate “Nguyen Huy" is provided in this record*

MODIFICATION OF POLYSULFONE ULTRAFILTRATION MEMBRANES WITH PVA AND TiO2 FOR BETTER ANTIFOULING

The objective of this study was to investigate anti-fouling property of modified polysulfone ultrafiltration  (UF) membranes.  Polysulfone UF membranes were modified  by  coating  a  thin film of polyvinyl alcohol (PVA), or a mixture of polyvinyl alcohol and titanium dioxide (TiO2) on  surface.  Effects  of  curing  temperature  on  the  coated  membranes  were  also  studied.  The modified  membranes  were  tested  with  0.5  g/L  sodium  alginate  solution  and  industrial  dye wastewater.  Curing  temperature  influenced  remarkably  flux  and  fouling  property  of  the membranes. Among experiments studied, 85 oC was the best curing temperature. The PVA and PVA/TiO2-coated membranes reduced fouling significantly. Dispersion of TiO2 nanoparticles on membrane surface improved considerably bacteria removal of the membranes

Red light emission of Mn doped beta-tricalcium phosphate -Ca3(PO4)2

This paper is the first report on the red light emission of manganese (Mn) doped beta-tricalcium phosphate (b-Ca3(PO4)2, TCP) synthesis by co-precipitation method followed by thermal annealing. The annealed Mn doped TCP phosphor showed dominant spheres with a diameter of about 500 nm. The influences of the Mn concentration, annealing temperature, and atmospheres on the photoluminescence intensities of the phosphors were investigated and the results indicate that the annealing temperatures and Mn concentrations are the main factors. The phosphor showed visible emission peaks appeared at about 660 nm and 580 nm results in from the 4T1-6A1 transitions within Mn2+ ion. The Mn-TCP phosphor may serve as a candidate for light-emitting diode application in agriculture lighting. Keywords. Hydroxyapatite; manganese; luminescence; tricalcium phosphate

Medication Adherence in Cardiovascular Diseases

Cardiovascular disease is a significant cause of death globally. While effective long-term medications that reduce the risk of morbidity and mortality related to cardiovascular disease are readily available, nonadherence to prescribed medications remains a significant reason for suboptimal management. Consequently, this might lead to increased morbidity and mortality and healthcare costs. Medication nonadherence causes are myriad and complicated, with factors at the patient, healthcare provider, and health system levels. Many clinical trials have investigated interventions to target these factors for improving medication adherence, including improving patient education, testing behavioral interventions, implementing medication reminder tools, reducing medication costs, utilizing social support, utilizing healthcare team members, and simplifying medication dosing regimens. This book chapter describes factors influencing medication adherence and highlights the impact of varying levels of adherence on patients’ clinical and economic outcomes. We also summarize interventions for improving medication adherence in cardiovascular disease

CHẾ TẠO VÀ TÍNH CHẤT CỦA VẬT LIỆU TỔ HỢP GRAPHENE – ỐNG NANO CÁCBON – HẠT NANO VÀNG

In this work, a composite nanomaterial consisting of graphene (Gr), double-wall carbon nanotube (DWCNTs) and gold nanoparticles (AuNPs), designated as DWCNTs-AuNPs-Gr was synthesized via the thermal chemical vapour deposition technique. The morphology and electrical and electrochemical properties of the material were characteried by using field emission scanning electron microscopy, Raman spectroscopy, four-probe sheet resistance measurement, and cyclic voltammetry (CV). The average sheet resistance value of DWCNTs-AuNPs-Gr is 549 W/sq, 2.3 times lower than that of graphene. The current response of a DWCNTs-AuNPs-Gr-modified electrode in a 2 mM K3[Fe(CN)6]/K4[Fe(CN)6] solution with 0.1 M PBS is 15.79 µA, 1.48 times higher than that of a graphene-modified electrode and 2.57 times higher than that of a bare electrode. The DWCNTs-AuNPs-Gr material can be used for electrochemical biosensors to detect various bioelements.Trong công trình này, màng tổ hợp của vật liệu graphene (Gr) – ống nano cácbon hai tường (DWCNT) và hạt nano kim loại vàng (AuNPs) (DWCNT-AuNPs-Gr) đã được chế tạo bằng phương pháp lắng đọng pha hơi nhiệt hóa học (CVD). Hình thái học bề mặt và các tính chất điện, điện hóa của vật liệu tổ hợp đã được khảo sát thông qua kính hiển vi điện tử quét phát xạ trường, phổ Raman, điện trở bốn mũi dò và kỹ thuật quét thế vòng (CV). Với nồng độ DWCNTs 0,3 g/L và tốc độ quay phủ 4000 vòng/phút, vật liệu DWCNTs-AuNPs-Gr có điện trở bề mặt giảm 2,3 lần so với màng Gr và đạt khoảng 549 W/sq; dòng đỉnh đáp ứng trong dung dịch 2 mM K3[Fe(CN)6]/K4[Fe(CN)6] trong 0,1 M PBS đạt 15,79 µA tại 50 mV/s, cao gấp 1,48 lần so với điện cực biến tính màng Gr và gấp 2,57 lần so với điện cực trần. Vật liệu DWCNTs-AuNPs-Gr có tiềm năng ứng dụng trong cảm biến điện hóa để phát hiện các phần tử sinh học khác nhau

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Background: Future trends in disease burden and drivers of health are of great interest to policy makers and the public at large. This information can be used for policy and long-term health investment, planning, and prioritisation. We have expanded and improved upon previous forecasts produced as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and provide a reference forecast (the most likely future), and alternative scenarios assessing disease burden trajectories if selected sets of risk factors were eliminated from current levels by 2050. Methods: Using forecasts of major drivers of health such as the Socio-demographic Index (SDI; a composite measure of lag-distributed income per capita, mean years of education, and total fertility under 25 years of age) and the full set of risk factor exposures captured by GBD, we provide cause-specific forecasts of mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) by age and sex from 2022 to 2050 for 204 countries and territories, 21 GBD regions, seven super-regions, and the world. All analyses were done at the cause-specific level so that only risk factors deemed causal by the GBD comparative risk assessment influenced future trajectories of mortality for each disease. Cause-specific mortality was modelled using mixed-effects models with SDI and time as the main covariates, and the combined impact of causal risk factors as an offset in the model. At the all-cause mortality level, we captured unexplained variation by modelling residuals with an autoregressive integrated moving average model with drift attenuation. These all-cause forecasts constrained the cause-specific forecasts at successively deeper levels of the GBD cause hierarchy using cascading mortality models, thus ensuring a robust estimate of cause-specific mortality. For non-fatal measures (eg, low back pain), incidence and prevalence were forecasted from mixed-effects models with SDI as the main covariate, and YLDs were computed from the resulting prevalence forecasts and average disability weights from GBD. Alternative future scenarios were constructed by replacing appropriate reference trajectories for risk factors with hypothetical trajectories of gradual elimination of risk factor exposure from current levels to 2050. The scenarios were constructed from various sets of risk factors: environmental risks (Safer Environment scenario), risks associated with communicable, maternal, neonatal, and nutritional diseases (CMNNs; Improved Childhood Nutrition and Vaccination scenario), risks associated with major non-communicable diseases (NCDs; Improved Behavioural and Metabolic Risks scenario), and the combined effects of these three scenarios. Using the Shared Socioeconomic Pathways climate scenarios SSP2-4.5 as reference and SSP1-1.9 as an optimistic alternative in the Safer Environment scenario, we accounted for climate change impact on health by using the most recent Intergovernmental Panel on Climate Change temperature forecasts and published trajectories of ambient air pollution for the same two scenarios. Life expectancy and healthy life expectancy were computed using standard methods. The forecasting framework includes computing the age-sex-specific future population for each location and separately for each scenario. 95% uncertainty intervals (UIs) for each individual future estimate were derived from the 2·5th and 97·5th percentiles of distributions generated from propagating 500 draws through the multistage computational pipeline. Findings: In the reference scenario forecast, global and super-regional life expectancy increased from 2022 to 2050, but improvement was at a slower pace than in the three decades preceding the COVID-19 pandemic (beginning in 2020). Gains in future life expectancy were forecasted to be greatest in super-regions with comparatively low life expectancies (such as sub-Saharan Africa) compared with super-regions with higher life expectancies (such as the high-income super-region), leading to a trend towards convergence in life expectancy across locations between now and 2050. At the super-region level, forecasted healthy life expectancy patterns were similar to those of life expectancies. Forecasts for the reference scenario found that health will improve in the coming decades, with all-cause age-standardised DALY rates decreasing in every GBD super-region. The total DALY burden measured in counts, however, will increase in every super-region, largely a function of population ageing and growth. We also forecasted that both DALY counts and age-standardised DALY rates will continue to shift from CMNNs to NCDs, with the most pronounced shifts occurring in sub-Saharan Africa (60·1% [95% UI 56·8–63·1] of DALYs were from CMNNs in 2022 compared with 35·8% [31·0–45·0] in 2050) and south Asia (31·7% [29·2–34·1] to 15·5% [13·7–17·5]). This shift is reflected in the leading global causes of DALYs, with the top four causes in 2050 being ischaemic heart disease, stroke, diabetes, and chronic obstructive pulmonary disease, compared with 2022, with ischaemic heart disease, neonatal disorders, stroke, and lower respiratory infections at the top. The global proportion of DALYs due to YLDs likewise increased from 33·8% (27·4–40·3) to 41·1% (33·9–48·1) from 2022 to 2050, demonstrating an important shift in overall disease burden towards morbidity and away from premature death. The largest shift of this kind was forecasted for sub-Saharan Africa, from 20·1% (15·6–25·3) of DALYs due to YLDs in 2022 to 35·6% (26·5–43·0) in 2050. In the assessment of alternative future scenarios, the combined effects of the scenarios (Safer Environment, Improved Childhood Nutrition and Vaccination, and Improved Behavioural and Metabolic Risks scenarios) demonstrated an important decrease in the global burden of DALYs in 2050 of 15·4% (13·5–17·5) compared with the reference scenario, with decreases across super-regions ranging from 10·4% (9·7–11·3) in the high-income super-region to 23·9% (20·7–27·3) in north Africa and the Middle East. The Safer Environment scenario had its largest decrease in sub-Saharan Africa (5·2% [3·5–6·8]), the Improved Behavioural and Metabolic Risks scenario in north Africa and the Middle East (23·2% [20·2–26·5]), and the Improved Nutrition and Vaccination scenario in sub-Saharan Africa (2·0% [–0·6 to 3·6]). Interpretation: Globally, life expectancy and age-standardised disease burden were forecasted to improve between 2022 and 2050, with the majority of the burden continuing to shift from CMNNs to NCDs. That said, continued progress on reducing the CMNN disease burden will be dependent on maintaining investment in and policy emphasis on CMNN disease prevention and treatment. Mostly due to growth and ageing of populations, the number of deaths and DALYs due to all causes combined will generally increase. By constructing alternative future scenarios wherein certain risk exposures are eliminated by 2050, we have shown that opportunities exist to substantially improve health outcomes in the future through concerted efforts to prevent exposure to well established risk factors and to expand access to key health interventions

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke